Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
other techniques and integrated into a comprehensive drug discovery or materials de-
sign pipeline.
7.6 Future directions and potential developments
of virtual screening of mucoadhesive polymers
The future perspectives of VS of mucoadhesive polymers hold great promise, as this
field continues to evolve and advance. Here are some key future directions and poten-
tial developments:
1. ML and AI integration: The integration of ML and AI techniques into VS processes
of mucoadhesive polymers can enhance the accuracy and efficiency of polymer se-
lection. ML models can be trained on large datasets of known mucoadhesive poly-
mers and used to predict the mucoadhesive properties of novel polymers, based on
their chemical structures [77]. This can help to identify promising mucoadhesive
polymers more rapidly.
2. High-throughput screening: Advances in computational power and automation
can enable high-throughput VS (HTVS) of mucoadhesive polymers [78]. This
means that researchers can efficiently screen a large number of polymers to iden-
tify potential mucoadhesive polymers for various drug delivery applications.
3. Personalized medicine: Tailoring mucoadhesive polymer formulations to indi-
vidual patient needs is an exciting prospect. VS can help identify polymers that
are well-suited for specific patient profiles, taking into account factors like muco-
sal characteristics, genetic factors, and disease conditions [79].
4. Nanotechnology integration: The combination of mucoadhesive polymers with
nanotechnology, such as nanoparticles and nanogels, holds great potential for tar-
geted drug delivery [80]. VS can play a crucial role in identifying polymer–nano-
particle combinations that offer optimal drug release and adherence to mucosal
surfaces [81].
5. Advanced MD simulations: MD simulations will become more sophisticated, al-
lowing researchers to simulate polymer–mucosal interactions with higher accu-
racy and at longer time scales [82]. This can provide deeper insights into the
behavior of mucoadhesive polymers in complex biological environments.
6. Biocompatible and biodegradable polymers: Future research may focus on the
development of mucoadhesive polymers that are not only effective but are also
biocompatible and biodegradable. These polymers could minimize potential side
effects and improve patient outcomes [83].
7. Translational research and clinical applications:VScanbridgethegapbe-
tween laboratory research and clinical applications [84]. Researchers can use
computational tools to desig n and optimize mucoadhesive polymer-based drug
delivery systems for specific medical conditions and diseases.
7 Virtual screening of mucoadhesive polymers 153
https://t.me/med1917
8. Regulatory considerations: As mucoadhesive polymer-based drug delivery sys-
tems advance, regulatory agencies will need to develop guidelines and standards
to ensure their safety and efficacy [85]. VS can aid in the design of preclinical and
clinical studies to meet these regulatory requirements.
9. Cross-disciplinary collaboration: Collaborations between researchers from dif-
ferent fields, such as polymer chemistry, pharmacology, and computational sci-
ence, will become increasingly important [85, 86]. This multidisciplinary approach
can lead to innovative solutions and breakthroughs in mucoadhesive polymer
research.
10. Environmental sustainability: The development of eco-friendly and sustainable
mucoadhesive polymers will likely gain importance in the future. Researchers
may use VS to identify polymers that are not only effective but also environmen-
tally responsible.
11. Combination therapy optimization: VS can be applied to optimize combination
therapies by identifying mucoadhesive polymers that can simultaneously deliver
multiple drugs with synergistic effects [87]. This approach is particularly relevant
for complex diseases.
12. Real-time monitoring: VS can be integrated with real-time monitoring technolo-
gies, such as biosensors or wearable devices, to track drug delivery and patient
responses [87]. This will enable healthcare providers to adjust treatment plans in
real time.
13. Gene delivery: Beyond drug delivery, VS can be extended to identify mucoadhe-
sive polymers suitable for gene therapy applications [88]. This has the potential to
revolutionize the treatment of genetic disorders and certain diseases.
Today, VS is a crucial component of the polymer discovery process. It is typically im-
plemented as a hie rarchical workflow, integrating various techniques as filters to
rank potentially active substances (either sequentially or concurrently).
The following methods are currently used to evaluate polymer likeness.
7.6.1 Counting scheme
The knowledge about the structure attributes of potential therapeutic compounds as
mucoadhesive polymers is often extracted from database collections of known drugs.
The profiles of molecular weight, lipophilicity, and charge are used to derive straight-
forward counting rules for the appropriate description of ADMET-related parame-
ters [89].
154 Gowtham Menon et al.
https://t.me/med1917
7.6.2 Functional group filters
Filters are used to remove substances that are reactive, poisonous, or otherwise inap-
propriate, like derivatives of natural products. Examples are reactive alkyl halide per-
oxide, carbazide, and other similar reactive functional groups; crown ethers, disulfide,
aliphatic methylene chains longer than seven, as well as disulfide and other unsuitable
leads [89]. Unsuitable natural products could contain quinones, polyenes, and cyclohex-
imidine derivatives that have been filtered out. A useful and quick method of condens-
ing a huge database is to screen out compounds that contain atom groups known to be
poisonous and related to toxicity [90]. An approach based on structure could be used to
assess compound toxicity with a better description of toxicity.
7.6.3 Topological classification
It is often anticipated that mucoadhesive polymers with a structure similar to a
known medicine will have drug-like features such as oral bioavailability, low toxicity,
membrane permeability, and metabolic stability. Its initial component is a highly fast
filter tool in VS systems, based on artificial neural networks (ANNs) and decision trees
[90]. Data is also gathered to identify structural motifs and pharmacophore character-
istics of small molecules that describe medications. VS of mucoadhesive polymers can
be used to analyze virtual libraries, based on the presence or absence of drug-like
frameworks, side chains, or structural motifs.
7.6.4 Pharmacophore points filter
Recently, a simple pharmacophore filter was introduced. It is predicated on the idea
that drug-like compounds have at least two different pharmacophore groups. Four
functional motifs have been identified that ensure hydrogen bonding capability,
which is required for the polymer molecule’s unique interaction with its biological
target. These motifs can be joined to form functional groups, known as pharmaco-
phore points, which include the following: amine amide, alcohol, ketone, sulfone, sul-
fonamide, carboxylic acid carbamate, guanidine, amidine, urea, and ester [91].
7.6.5 Scoring functions: physics-, empirical-,
and knowledge-based
Physical approach es rely on molecular mechanics force fields. In short, nonbonded
interaction terms such as Van der Waals interactions, electrostatics, and hydrogen
bonds are added together [92]. Similarly, empirical scoring functions add up weighted
7 Virtual screening of mucoadhesive polymers 155
https://t.me/med1917
energy terms. Items describing rotatable bonds or solvent-accessible surface area are
also added, and all terms are parameterized against experimental binding affinities.
ML has been widely used to speed up the VS of organic materials in a variety of
disciplines. Nagasawa et al. collected experimental findings of over 1200 conjugated
polymers from 500 publications; the metrics comprised band gaps – the energetic sep-
aration between the filled valence and empty conduction bands of the bulk solid-state
material [93].
7.6.6 Molecular weights, energy levels, and chemical
structural fingerprints
The goal of ML is to learn a task from data by optimizing a performance metric. There
are three major approaches: (1) Unsupervised learning, in which the goal is to dis-
cover patterns in the underlying structure and improve data interpretability; (2) rein-
forcement learning, in which an agent evolves in a given context and utilizes data
gleaned from previous experience; and (3) supervised learning, in which an algorithm
is trained using inputs from the user [94]. A subset of ML known as deep learning
(DL) combines the input information using hidden layers to create a network. The net-
work then receives and processes the information. The nonlinearities produce a
highly adaptable predictive model that can recognize intricate patterns.
7.6.7 Neural networks
ANNs, also known as neural networks (NNs), are models that take a set of features as
input and carry o ut mathematical operations using a set of parameters. The final
layer, or hidden layer, should take into account the goal prediction, such as regression
or classification. The hidden layer is the series of calculations between the input and
the output [95]. The network’s nonlinearities, referred to as activation functions, keep
an eye on the data as it moves through it and decide whether or not it can move on to
the following layer.
Following are some ways in which this set of DL models can be divided.
– Convolutional NNs
– Recurrent NNs
– Graph NNs
7.6.8 High-throughput virtual screening
High-throughput virtual screening (HTVS) has emerged as a strong method in a wide
range of materials discovery applications finding of potential candidate material is
156 Gowtham Menon et al.
https://t.me/med1917
the main area of interest. In the initial screening stage, low-cost procedures are used
to identify potential leads, which are subsequently processed using more precise, ex-
pensive procedures to refine predicted properties. HTVS is used to explore huge, com-
plicated chemical environments to speed up the finding of interesting compounds and
cut down on time wasted on dead ends [96].
On the other hand, polymeric material techniques continue to be difficult. Com-
putations on polymers are inherently more expensive than computations on small(er)
molecules due to the size of the necessary oligomeric models, in addition to the wide
variety of monomer sequences and compositions and the potential for overall disar-
ray. Further, a disproportionately high number of calculations may be required due
to the vast array of possible monomer sequences and compositions as well as the po-
tential for disorder within polymer chains. A pool of 500 symmetric monomer units,
for instance, can be used to create 120,000 simple, ordered two-component copoly-
mers. There are more than 20 million possible polymers when three-component co-
polymers for the same monomer pool are considered.
7.7 Conclusion
In conclusion, the future of VS of mucoadhesive polymers is marked by technological
advancements, interdisciplinary collaboration, and a focus on personalized medicine
and sustainability. These developments have the potential to revolutionize drug deliv-
ery systems and improve the effectiveness of treatments for a wide range of medical
conditions. The future of VS for mucoadhesive polymers is likely to be marked by in-
creased precision, efficiency, and customization in the development of drug delivery
systems and medical devices. This can ultimately lead to better healthcare outcomes,
improved patient compliance, and reduced side effects. However, it is important to
remember that while VS can greatly accelerate the development process of mucoad-
hesive polymers, experimental validation will remain a crucial step in ensuring the
safety and efficacy of these materials in real-world applications.
References
[1] Gaikwad, S. S., Thombre, S. K., Kale, Y. K., Gondkar, S. B., & Darekar, A. B. Design and in vitro
characterization of mucoadhesive tablets of timolol maleate. Drug Development and Industrial
Pharmacy, 2014, 40(5), 680–690.
[2] Asane, G. S., Nirmal, S. A., Rasal, K. B., Naik, A. A., Mahadik, M. S., & Rao, Y. M. Polymers for
mucoadhesive drug delivery system: A current status. Drug Development and Industrial Pharmacy,
2008, 34(11), 1246–1266.
[3] Sachin, G., Yogesh, K. K., Sheeta, B. G., & Avinash, B. D. Buccal tablet as a promising mucoadhesive
drug delivery. Inventi Rapid: Pharm Tech, 2012, 3, 1–9.
7 Virtual screening of mucoadhesive polymers 157
https://t.me/med1917
[4] Nukoolkarn, V., Lee, V. S., Malaisree, M., et al. Molecular dynamic simulations analysis of ritronavir
and lopinavir as SARS-CoV 3CLpro inhibitors. Journal of Theoretical Biology, 2008, 254, 861–867.
[5] Eleftheriadis, G. K., Monou, P. K., Bouropoulos, N., Boetker, J., Rantanen, J., Jacobsen, J., Vizirianakis,
I. S., & Fatouros, D. G. Fabrication of mucoadhesive buccal films for local administration of
ketoprofen and lidocaine hydrochloride by combining fused deposition modeling and inkjet
printing. Journal Pharmaceutical Sciences, 2020, 109, 2757– 2766.
[6] Koradia, H., & Chaudhari, K. Formulation of unidirectional buccal tablet of Mirtazapine: An in vitro
and ex vivo evaluation. Journal of Drug Delivery Science and Technology, 2018, 43, 233–242.
[7] Marques, A. C., Rocha, A. I., Leal, P., Estanqueiro, M., & Lobo, J. M. S. Development and
characterization of mucoadhesive buccal gels containing lipid nanoparticles of ibuprofen.
International Journal of Pharmaceutics, 2017, 533, 455–462.
[8] Laffleur, F. Mucoadhesive therapeutic compositions: A patent review (2011–2014). Expert Opinion on
Therapeutic Patents, 2016, 26(3), 377–388.
[9] Brako, F., Thorogate, R., Mahalingam, S., Raimi-Abraham, B., Craig, D. Q. M., & Edirisinghe,
M. Mucoadhesion of progesterone-loaded drug delivery nanofiber constructs. ACS Applied
Materials and Interfaces, 2018, 10(16), 13381–13389.
[10] Komati, S., Swain, S., Rao, M. E. B., Jena, B. R., & Dasi, V. Mucoadhesive multiparticulate drug
delivery systems: An extensive review of patents. Advanced Pharmaceutical Bulletin, 2019, 9(4),
521–538.
[11] Bappaditya, C., Nursazreen, A., Pinaki, S., & Uttam Kumar, M. Mucoadhesive polymers and their
mode of action: A recent update. Journal of Applied Pharmaceutical Sciences, 2017, 7(5), 195–203.
[12] Carmen, M. G., & Pilar, M. M. Enhancement of oral bioavailability of natural compounds and
probiotics by mucoadhesive tailored biopolymer-based nanoparticles: A review. Food Hydrocolloids,
2021, 118, 1–17.
[13] Subramanian, P. Mucoadhesive delivery system: A smart way to improve bioavailability of
nutraceuticals. Foods, 2021, 10(6), 1362–1384.
[14] Lam, J. K. W., Xu, Y., Worsley, A., & Wong, I. C. K. Oral transmucosal drug delivery for pediatric use.
Advanced Drug Delivery Reviews, 2014, 73, 50 –62.
[15] Corthésy, B., & Bioley, G. Lipid-based particles: Versatile delivery systems for mucosal vaccination
against infection. Frontiers Immunology, 2018, 9, 431.
[16] Longet, S., Lundahl, M. L. E., & Lavelle, E. C. Targeted strategies for mucosal vaccination.
Bioconjugate Chemistry, 2018, 29, 613–623.
[17] Woodrow, K. A., Bennett, K. M., & Lo, D. D. Mucosal vaccine design and delivery. Annual Review of
Biomedical Engineering, 2012, 14, 17– 46.
[18] Andrianov, A. K., & Payne, L. G. Polymeric carriers for oral uptake of microparticulates. Advanced
Drug Delivery Reviews, 1998, 34, 155–170.
[19] Dewangan, H. K. Rational application of nanoadjuvant for mucosal vaccine delivery system. Journal
of Immunological Methods, 2020, 481, 1–12.
[20] Lycke, N. Recent progress in mucosal vaccine development: Potential and limitations. Nature
Reviews Immunology, 2012, 12, 592–605.
[21] Wang, B., Zhang, K., Wang, J., Zhao, R., Zhang, Q., & Kong, X. Poly(Amidoamine)-modified
mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder
cancer therapy. Colloid Surfaces B: Biointerfaces, 2020, 189, 110832.
[22] Kolawole, O. M., Lau, W. M., & Khutoryanskiy, V. V. Chitosan/β-glycerophosphate in situ gelling
mucoadhesive systems for intravesical delivery of Mitomycin-C. International Journal of
Pharmaceutics, 2019, 1, 100007.
[23] Cevher, E., Taha, M. A., Orlu, M., & Araman, A. Evaluation of mechanical and mucoadhesive
properties of clomiphene citrate gel formulations containing carbomers and their thiolated
derivatives. Drug Delivery, 2008, 15, 57–67.
158 Gowtham Menon et al.
https://t.me/med1917
[24] Khan, A. B., Mahamana, R., & Pal, E. Review on mucoadhesive drug delivery system: Novel
approaches in modern era. RGUHS Journal of Pharmaceutical Sciences, 2014, 4, 128–141.
[25] Gu, J. M., Robinson, J. R., & Leung, S. H. Binding of acrylic polymers to mucin/epithelial surfaces:
Structure-property relationships. Critical Reviews in Therapeutic Drug Carrier Systems, 1988, 5,
21–67.
[26] Kumar, K., Dhawan, N., Sharma, H., Vaidya, S., & Vaidya, B. Bioadhesive polymers: Novel tool for
drug delivery. Artificial Cells, Nanomedicine, and Biotechnology, 2014, 42(4), 274–283.
[27] Ways, T. M. M., Lau, W. M., & Khutoryanskiy, V. V. Chitosan and its derivatives for application in
mucoadhesive drug delivery systems. Polymers, 2018, 10, 267.
[28] Mohamad, S. A., Abdelkader, H., Elrehany, M., & Mansour, H. F. Vitamin B12 buccoadhesive tablets:
Auspicious non-invasive substitute for intra muscular injection: Formulation, in vitro and in vivo
appraisal. Drug Development and Industrial Pharmacy, 2019, 45, 244–251.
[29] Jawadi, Z., Yang, C., Haidar, Z. S., Santa Maria, P. L., & Massa, S. Bio-inspired muco-adhesive
polymers for drug delivery applications. Polymers (Basel), 2022, 14(24), 5459.
[30] Chandrashekar, A., Annigeri, R. G., Va, U., & Thimmasetty, J. A. Clinicobiochemical evaluation of
curcumin as gel and as buccal mucoadhesive patches in the management of oral submucous
fibrosis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 2021, 131,
428–434.
[31] Prezotti, F. G., Siedle, I., Boni, F. I., Chorilli, M., Muller, I., & Cury, B. S. F. Mucoadhesive films based
on gellan gum/pectin blends as potential platform for buccal drug delivery. Pharm Development
and Technology, 2020, 25, 159– 167.
[32] Bhagurkar, M. A., Darji, M., Lakhani, P., Thipsay, P., Bandari, S., & Repka, M. A. Effects of formulation
composition on the characteristics of mucoadhesive films prepared by hot-melt extrusion
technology. Journal of Pharmacy and Pharmacology, 2018, 71, 293–305.
[33] Yuki, Y., & Kiyono, H. Mucosal vaccines: Novel advances in technology and delivery. Expert Review of
Vaccine, 2009, 8, 1083–1095.
[34] Bassi da Silva, J., Ferreira, S. B. S., Freitas, O., & Bruschi, M. L. A critical review about methodologies
for the analysis of mucoadhesive properties of drug delivery systems. Drug Development and
Industrial Pharmacy, 2017, 43, 1053–1070.
[35] Roy, S., Pal, K., Anis, A., Pramanik, K., & Prabhakar, B. Polymers in mucoadhesive drug-delivery
systems: A brief note. Designed Monomers and Polymers, 2009, 12, 483–495.
[36] Mishra, R., Banthia, A., & Majeed, A. Pectin based formulations for biomedical applications: A
review. Asian Journal of Pharmaceutical and Clinical Research, 2012, 5, 1–7.
[37] Mishra, R. K., Majeed, A. B. A., & Banthia, A. K. Development and characterization of pectin/gelatin
hydrogel membranes for wound dressing. International Journal of Plastics Technology, 2011, 15,
82–95.
[38] Duan, Y., Cai, X., Du, H., & Zhai, G. Novel in situ gel systems based on P123/TPGS mixed micelles and
gellan gum for ophthalmic delivery of curcumin. Colloid Surface B, 2015, 128, 322–330.
[39] Eouani, C., Piccerelle, P., Prinderre, P., Bourret, E., & Joachim, J. In-vitro comparative study of buccal
mucoadhesive performance of different polymeric films. European Journal of Pharmaceutics and
Biopharmaceutics, 2001, 52(1), 45–55.
[40] Ìkinci, G., Şenel, S., Wilson, C., & Şumnu, M. Development of a buccal bioadhesive nicotine tablet
formulation for smoking cessation. International Journal of Pharmaceutics, 2004, 277, 173– 178.
[41] Schneider, G., & Fechner, U. Computer-based de novo design of drug-like molecules. Nature
Reviews of Polymer Discovery, 2005, 4, 649–663.
[42] Leelananda, S. P., & Lindert, S. Computational methods in polymer discovery. Beilstein Journal of
Organic Chemistry, 2016, 12, 2694–2718.
[43] Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. Advancing Drug Discovery via Artificial
Intelligence. Trends in Pharmacological Sciences, 2019, 40, 592–604.
7 Virtual screening of mucoadhesive polymers 159
https://t.me/med1917
[44] Chao, W. R., Yean, D., Amin, K., Green, C., & Jong, L. Computer-aided rational drug design: A novel
agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol
to block akt signaling. Journal of Medicinal Chemistry, 2007, 50, 3412–3415.
[45] Chen, J., & Lai, L. Pocket v.2: Further developments on receptor-based pharmacophore modeling.
Journal of Chemical Information & Modeling, 2006, 46, 2684 –2691.
[46] Ballester, P. J. Machine learning for molecular modelling in drug design. Biomolecules, 2019, 9, 216.
[47] Buchete, N. V., & Hummer, G. Peptide folding kinetics from replica exchange molecular dynamics.
Physical Review E, 2008, 77, 030902.
[48] Hernández-Rodríguez, M., Rosales-Hernández, M., Mendieta-Wejebe, J., Martínez-Archundia, M., &
CorreaBasurto, J. Current tools and methods in Molecular Dynamics (MD) simulations for drug
design. Current Medicinal Chemistry, 2016, 23, 3909–3924.
[49] Mortier, J., Rakers, C., Bermudez, M., Murgueitio, M. S., Riniker, S., & Wolber, G. The impact of
molecular dynamics on drug design: Applications for the characterization of ligand–macromolecule
complexes. Drug Discovery Today: Technologies, 2015, 20, 686–702.
[50] Cwl, H., Soon, D., Caals, K., & Kapur, J. Governance of automated image analysis and artificial
intelligence analytics in healthcare. Clinical Radiology, 2019, 74, 329–337.
[51] Yu, W., Guvench, O., & MacKerell, A. D. Computational Approaches for the Design of Protein–Protein
Interaction Inhibitors- Understanding and Exploiting Protein–Protein Interactions as Polymer
Targets. 2013, Future Science Ltd: London, UK.
[52] Baum, Z. J., et al. Artificial intelligence in chemistry: Current trends and future directions. Journal of
Chemical Information and Modeling, 2021, 61, 3197–3212.
[53] Zhao, W., Hevener, K. E., White, S. W., Lee, R. E., & Boyett, J. M. A statistical framework to evaluate
virtual screening. BMC Bioinformatic, 2009, 10, 1–13.
[54] Gowthaman, R., Lyskov, S., & Karanicolas, J. DARC 2.0: Improved docking and virtual screening at
protein interaction sites. PLoS One, 2015, 10, 1–24.
[55] Mck, N., Fong, S., & Siu, S. W. I. PSOVina: The hybrid particle swarm optimization algorithm for
protein-ligand docking. Journal of Bioinformatics and Computational Biology, 2015, 13, 1541007.
[56] Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. Molecular docking and structure-based drug
design strategies. Molecules, 2015, 20 (7),13384–13421.
[57] Geng, C., Jung, Y., Renaud, N., Honavar, V., & Bonvin, A. M. J. J. Xue LC iScore: A novel graph kernel-
based function for scoring protein-protein docking models. Bioinformatics, 2019, 36, 112–121.
[58] Hawkins, P. C. D., Warren, G. L., Skillman, A. G., & Nicholls, A. How to do an evaluation: Pitfalls and
traps. Journal of Computer-Aided Molecular Design, 2008, 22, 179 –190.
[59] Grosdidier, A., Zoete, V., & Michielin, O. SwissDock, a protein-small molecule docking web service
based on EADock DSS. Nucleic Acids Research, 2011, 39, 270–277.
[60] Haga, J. H., Ichikawa, K., & Date, S. Virtual screening techniques and current computational
infrastructures. Current Pharmaceutical Design, 2016, 22, 3576– 3584.
[61] Hamza, A., Wei, N. N., & Zhan, C. G. Ligand-based virtual screening approach using a new scoring
function. Journal of Chemical Information & Modeling, 2012, 52, 963–974.
[62] Leelananda, S. P., & Lindert, S. Computational methods in drug discovery. Beilstein Journal of
Organic Chemistry, 2016, 12, 2694–2718.
[63] Leisinger, K. M., Garabedian, L. F., & Wagner, A. K. Improving access to medicines in low and middle
income countries: Corporate responsibilities in context. Southern Med Review, 2012, 5, 3–8.
[64] Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. Structure based virtual screening for drug
discovery: Principles, applications and recent advances. Current Topics in Medicinal Chemistry, 2014,
14, 1923–1938.
[65] Sengupta, S., & Bandyopadhyay, S. Application of support vector machines in virtual screening.
International Journal of Computational Biology, 2014, 1, 56–62.
160 Gowtham Menon et al.
https://t.me/med1917
[66] Zhao, Y., & Sanner, M. F. FLIPDock: Docking flexible ligands into flexible receptors. Proteins
Structure Funct Bioinforma, 2007, 68, 726–37.
[67] Shin, W. H., Heo, L., Lee, J., Ko, J., Seok, C., & Lee, J. LigDockCSA: Protein-ligand docking using
conformational space annealing. Journal of Computational Chemistry, 2011, 32, 3226–3232.
[68] Prajapat, M., Shekhar, N., Sarma, P., et al. Virtual screening and molecular dynamics study of
approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
Journal of Molecular Graphics and Modelling, 2020, 101, 107716.
[69] Vilar, S., Cozza, G., & Moro, S. Medicinal chemistry and the molecular operating environment (MOE):
Application of QSAR and molecular docking to drug discovery. Current Topics in Medicinal
Chemistry, 2008, 8, 1555–1572.
[70] Sliwoski, G., Kothiwale, S., Meiler, J., Edward, W., & Lowe, J. Computational methods in drug
discovery. Pharmacol Reviews, 2013, 66, 334–395.
[71] Spitzer, R., & Jain, A. N. Surflex-Dock: Docking benchmarks and real-world application. Journal of
Computer-Aided Molecular Design, 2012, 26, 687–699.
[72] Sridhar, D. Improving access to essential medicines: How health concerns can be prioritised in the
global governance system. Public Health Ethics, 2008, 1, 83–88.
[73] Sterling, T., & Irwin, J. J. ZINC15–ligand discovery for everyone. Journal of Chemical Information &
Modeling, 2015, 55, 2324–2337.
[74] Trott, O., & Olson, A. J. AutoDock vina: Improving the speed and accuracy of docking with a new
scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry,
2009, 31, 455–461.
[75] Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today, 2006, 11,
1046–1053.
[76] Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, R., et al. DrugBank 5.0: A major
update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46, 1074–1082.
[77] Rantanen, J., & Khinast, J. The future of pharmaceutical manufacturing sciences. Journal
Pharmaceutical Sciences, 2015, 104(11), 3612–3638.
[78] Greenhill, A. T., & Edmunds, B. R. A primer of artificial intelligence in medicine. Techniques and
Innovations in Gastrointestinal Endoscopy, 2020, 22(2), 85– 89.
[79] Anthony, C. C. Big data in medicine: The upcoming artificial intelligence. Progress in Pediatric
Cardiology, 2016, 43, 91–94.
[80] Abu-Elezz, I., Hassan, A., Nazeemudeen, A., et al. The benefits and threats of blockchain technology
in healthcare: A scoping review. International Journal of Medical Informatics, 2020, 142, 104246.
[81] Elbadawi, M., Gaisford, S., & Basit, A. W. Advanced machine-learning techniques in drug discovery.
Drug Discovery Today: Technologies, 2021, 26(3), 769 – 777.
[82] Margulis, E., Dagan-Wiener, A., Ives, R. S., et al. Intense bitterness of molecules: Machine learning
for expediting drug discovery. Computational and Structural Biotechnology Journal, 2020, 19,
568–576.
[83] Paul, D., Sanap, G., Shenoy, S., et al. Artificial intelligence in drug discovery and development. Drug
Discovery Today: Technologies, 2021, 26(1), 80–93.
[84] Dnyaneshwar, K., Gaurav, S., Debleena, P., et al. Artificial intelligence in the pharmaceutical sector:
Current scene and future prospect. In The Future of Pharmaceutical Product Development and
Research. 2020, (pp. 73–107). Elsevier.
[85] Bender, A., & Cortes-Ciriano, I. Artificial intelligence in drug discovery: What is realistic, what are
illusions? Part 2: A discussion of chemical and biological data. Drug Discovery Today: Technologies,
2021, 26(4), 1040–1052.
[86] Pu, L., Naderi, M., Liu, T., et al. eToxPred: A machine learning-based approach to estimate the
toxicity of drug candidates. BMC Pharmacology and Toxicology, 2019, 20(1), 2.
7 Virtual screening of mucoadhesive polymers 161
https://t.me/med1917
[87] Lee, H., & Kim, W. Comparison of target features for predicting drug-target interactions by deep
neural network based on large-scale drug-induced transcriptome data. Pharmaceutics, 2019,
11(8), 377.
[88] Mak, K. K., & Pichika, M. R. Artificial intelligence in drug development: Present status and future
prospects. Drug Discovery Today: Technologies, 2019, 24(3), 773–780.
[89] Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., et al. Deep learning enables rapid identification of
potent DDR1 kinase inhibitors. Nature Biotechnology, 2019, 37(9), 1038–1040.
[90] Maram, Y., & Hamdy, H. The role of artificial intelligence in revealing the results of the interaction of
biological materials with each other or with chemicals. Materials Today: Proceedings, 2021, 45,
4954–4959.
[91] Wójcikowski, M., Ballester, P. J., & Siedlecki, P. Performance of machine-learning scoring functions in
structure-based virtual screening. Scientific Reports, 2017, 7, 1–10.
[92] Pyzer-Knapp, E. O., Li, K., & Aspuru-Guzik, A. Learning from the Harvard clean energy project: The
use of neural networks to accelerate materials discovery. Advanced Functional Materials, 2015,
25(41), 6495–6502.
[93] Nagasawa, S., Al-Naamani, E., & Saeki, A. Computer-aided screening of conjugated polymers for
organic solar cell: Classification by random forest. Journal of Phy Chem Let, 2018, 9, 2639–2646.
[94] Khan, S. R., Al Rijjal, D., Piro, A., & Wheeler, M. B. Integration of AI and traditional medicine in
polymerdiscovery. Polymer Discovery Today, 2021, 26, 982–992.
[95] Refaey, R. H., El-Ashrey, M. K., Nissan, Y. M., et al. Repurposing of renin inhibitors as SARS-COV-2
main protease inhibitors: A computational study. Virology, 2021, 554, 48–54.
[96] Von Lilienfeld, O. A. Quantum machine learning in chemical compound space. Angewandte Chemie
International Edition, 2018, 57, 4164–4169. Acc. 2020, 139, 36.
162 Gowtham Menon et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана